User login
Among patients with multiple sclerosis (MS) treated with interferon beta-1b, higher 25(OH)D levels were associated with lower rates of MS activity observed on MRI, according to a study of 1,482 patients with relapsing-remitting MS treated with interferon beta-1b. Researchers found:
• Average 25(OH)D levels were significantly inversely correlated with the cumulative number of new active lesions between baseline and the last MRI.
• A 50.0-nmol/L increase in serum 25(OH)D levels was associated with a 31% lower rate of new lesions.
• The lowest rate of new lesions was seen in patients with 25(OH)D levels greater than 100.0 nmol/L.
• No significant associations were seen between 25(OH)D levels and change in brain volume, relapse rates, or Expanded Disability Status Scale score.
• Results were consistent following adjustments for DRB1*15 or vitamin D-binding protein status.
Citation: Fitzgerald KC, Menger KL, Kӧchert K, et al. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. [Published online ahead of print October 12, 2015]. JAMA Neurol. doi: 10.1001/jamaneurol.2015.2742.
Among patients with multiple sclerosis (MS) treated with interferon beta-1b, higher 25(OH)D levels were associated with lower rates of MS activity observed on MRI, according to a study of 1,482 patients with relapsing-remitting MS treated with interferon beta-1b. Researchers found:
• Average 25(OH)D levels were significantly inversely correlated with the cumulative number of new active lesions between baseline and the last MRI.
• A 50.0-nmol/L increase in serum 25(OH)D levels was associated with a 31% lower rate of new lesions.
• The lowest rate of new lesions was seen in patients with 25(OH)D levels greater than 100.0 nmol/L.
• No significant associations were seen between 25(OH)D levels and change in brain volume, relapse rates, or Expanded Disability Status Scale score.
• Results were consistent following adjustments for DRB1*15 or vitamin D-binding protein status.
Citation: Fitzgerald KC, Menger KL, Kӧchert K, et al. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. [Published online ahead of print October 12, 2015]. JAMA Neurol. doi: 10.1001/jamaneurol.2015.2742.
Among patients with multiple sclerosis (MS) treated with interferon beta-1b, higher 25(OH)D levels were associated with lower rates of MS activity observed on MRI, according to a study of 1,482 patients with relapsing-remitting MS treated with interferon beta-1b. Researchers found:
• Average 25(OH)D levels were significantly inversely correlated with the cumulative number of new active lesions between baseline and the last MRI.
• A 50.0-nmol/L increase in serum 25(OH)D levels was associated with a 31% lower rate of new lesions.
• The lowest rate of new lesions was seen in patients with 25(OH)D levels greater than 100.0 nmol/L.
• No significant associations were seen between 25(OH)D levels and change in brain volume, relapse rates, or Expanded Disability Status Scale score.
• Results were consistent following adjustments for DRB1*15 or vitamin D-binding protein status.
Citation: Fitzgerald KC, Menger KL, Kӧchert K, et al. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. [Published online ahead of print October 12, 2015]. JAMA Neurol. doi: 10.1001/jamaneurol.2015.2742.